You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HIV Seronegativity

Showing 1 - 25 of 8,134
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIV Incidence and Participation Retention in Pune, India

Completed
  • HIV Infections
  • HIV Seronegativity
    • Pune, India
      National AIDS Research Institute
    Aug 25, 2022

    HIV, Pregnancy, HIV Seronegativity Trial (MF59, rgp120/HIV-1 SF-2)

    Withdrawn
    • HIV Infections
    • +2 more
    • MF59
    • rgp120/HIV-1 SF-2
    • (no location specified)
    Oct 28, 2021

    HIV, HIV Seronegativity Trial in Baltimore (Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59)

    Completed
    • HIV Infections
    • HIV Seronegativity
    • Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)
    • +3 more
    • Baltimore, Maryland
      JHU AVEG
    Oct 27, 2021

    HIV, Pregnancy, HIV Seronegativity Trial in New Haven, Nashville (gp160 Vaccine (MicroGeneSys))

    Completed
    • HIV Infections
    • +2 more
    • gp160 Vaccine (MicroGeneSys)
    • New Haven, Connecticut
    • +1 more
    Oct 27, 2021

    HIV, HIV Seronegativity Trial in Saint Louis, Seattle (gp160 Vaccine (Immuno-AG))

    Completed
    • HIV Infections
    • HIV Seronegativity
    • gp160 Vaccine (Immuno-AG)
    • Saint Louis, Missouri
    • +1 more
    Oct 28, 2021

    HIV, HIV Seronegativity Trial in Worldwide (ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1, ALVAC(2)120(B,MN)GNP (vCP1452) )

    Completed
    • HIV Infections
    • HIV Seronegativity
    • ALVAC(2)120(B,MN)GNP (vCP1452)
    • +3 more
    • Rio de Janeiro, Brazil
    • +3 more
    Oct 13, 2021

    HIV, HIV Seronegativity Trial in Rochester, Nashville, Seattle (Env 2-3)

    Completed
    • HIV Infections
    • HIV Seronegativity
    • Env 2-3
    • Rochester, New York
    • +2 more
    Oct 26, 2021

    HIV, HIV Seronegativity Trial in United States (ALVAC-HIV MN120TMG (vCP205))

    Completed
    • HIV Infections
    • HIV Seronegativity
    • ALVAC-HIV MN120TMG (vCP205)
    • Birmingham, Alabama
    • +5 more
    Oct 28, 2021

    HIV Seronegativity, Linkage Trial in Los Angeles, San Diego (T-POWr Intervention)

    Completed
    • HIV Seronegativity
    • Linkage
    • T-POWr Intervention
    • Los Angeles, California
    • +1 more
    Sep 9, 2021

    HIV, HIV Seronegativity Trial in United States (HIV p24/MF59 Vaccine, ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein

    Completed
    • HIV Infections
    • HIV Seronegativity
    • HIV p24/MF59 Vaccine
    • +3 more
    • Birmingham, Alabama
    • +6 more
    Oct 27, 2021

    HIV, HIV Seronegativity Trial in Rochester, Nashville, Seattle (MTP-PE/MF59, Env 2-3)

    Completed
    • HIV Infections
    • HIV Seronegativity
    • MTP-PE/MF59
    • Env 2-3
    • Rochester, New York
    • +2 more
    Oct 28, 2021

    HIV, HIV Seronegativity Trial in United States (ALVAC(2)120(B,MN)GNP (vCP1452))

    Completed
    • HIV Infections
    • HIV Seronegativity
    • ALVAC(2)120(B,MN)GNP (vCP1452)
    • Birmingham, Alabama
    • +12 more
    Oct 13, 2021

    HIV, HIV Seronegativity Trial in United States (ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1, ALVAC-HIV

    Completed
    • HIV Infections
    • HIV Seronegativity
    • ALVAC(2)120(B,MN)GNP (vCP1452)
    • +2 more
    • Long Beach, California
    • +16 more
    Oct 27, 2021

    Patient Adherence, HIV Seronegativity Trial in Los Angeles, San Diego, Torrance (brief Motivational Interviewing)

    Completed
    • Patient Adherence
    • HIV Seronegativity
    • brief Motivational Interviewing
    • Los Angeles, California
    • +4 more
    Sep 9, 2021

    PrEP Uptake, HIV Seronegativity Trial in San Diego (Informed Risk Score)

    Completed
    • PrEP Uptake
    • HIV Seronegativity
    • Informed Risk Score
    • San Diego, California
      University of California, San Diego
    May 8, 2020

    Screening Protocol for HIV Vaccine Studies

    Completed
    • HIV Seronegativity
    • HIV Infections
      • Bethesda, Maryland
        National Institutes of Health Clinical Center, 9000 Rockville Pi
      Dec 4, 2019

      Patient Adherence, HIV Seronegativity Trial in United States (SoC + iTab)

      Completed
      Has Results
      • Patient Adherence
      • HIV Seronegativity
      • SoC + iTab
      • Long Beach, California
      • +3 more
      Jun 18, 2020

      HIV Trial in Boston (TRUVADA + raltegravir)

      Completed
      Has Results
      • HIV Infections
      • TRUVADA + Raltegravir
      • Boston, Massachusetts
        Fenway Community Health
      Oct 4, 2022

      HIV Seropositivity, Lower Urinary Tract Symptoms Trial (Questionnaires)

      Not yet recruiting
      • HIV Seropositivity
      • Lower Urinary Tract Symptoms
      • Questionnaires
      • (no location specified)
      Jul 19, 2023

      The Women's HIV SeroIncidence Study (ISIS)

      Completed
      • HIV Infections
        • Washington, District of Columbia
        • +8 more
        Aug 25, 2022

        HIV Trial in Rochester, Nashville, Seattle (HIV-1 C4-V3 Polyvalent Peptide Vaccine)

        Completed
        • HIV Infections
        • HIV-1 C4-V3 Polyvalent Peptide Vaccine
        • Rochester, New York
        • +2 more
        Oct 27, 2021

        HIV Trial in United States (MF59, rgp120/HIV-1 SF-2)

        Completed
        • HIV Infections
        • MF59
        • rgp120/HIV-1 SF-2
        • Birmingham, Alabama
        • +3 more
        Oct 27, 2021

        HIV Trial in United States (Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A, NefTat, AS02A Adjuvant)

        Completed
        • HIV Infections
        • Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A
        • +3 more
        • Birmingham, Alabama
        • +14 more
        Oct 13, 2021

        HIV Trial in United States (APL 400-047, ALVAC-HIV MN120TMG (vCP205), Sargramostim)

        Completed
        • HIV Infections
        • APL 400-047
        • +2 more
        • Birmingham, Alabama
        • +3 more
        Oct 28, 2021

        HIV Trial in Rochester (HIV p17/p24:Ty-VLP, Aluminum hydroxide)

        Completed
        • HIV Infections
        • HIV p17/p24:Ty-VLP
        • Aluminum hydroxide
        • Rochester, New York
          Univ. of Rochester AVEG
        Oct 28, 2021